Archive
16.03.2010
4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5 mio (CHF 266mio) for 4-Antibody
more...21.09.2009
4-Antibody received notice of allowance for U.S. patent application describing the Hu-PAC® technology
more...11.09.2009
Retrocyte Display® technology patent applications published
more...26.09.2008
September 26, 2008: 4-Antibody appoints Dr Richard Mason as new Chief Executive Officer
more...08.11.2007
Don Drakeman joins 4-Antibody Board
more...15.01.2007
4-Antibody AG closes CHF 17 Million Series A, bringing the total Series A financing to CHF 23 Million ($18.5 Million)
more...21.08.2006
4-Antibody AG closes CHF 6 Million Series A financing and appoints Sijmen de Vries as CEO
more...10.08.2005
4-Antibody has formally constituted Scientific Advisory Board
more...13.07.2005
4-Antibody receives European patent for its core technology platform allowing the development and optimization of fully human antibody drugs.
more...10.03.2005
4-Antibody finalizes placement of CHF 0.5 million among a group of private investors.
more...Back